<DOC>
	<DOCNO>NCT00391274</DOCNO>
	<brief_summary>The purpose study compare efficacy toxicity pemetrexed docetaxel administer 3-weekly schedule treatment patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) prior chemotherapy .</brief_summary>
	<brief_title>Chemotherapy Patients With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis NSCLC ( Stage IIIA , IIIB , IV ) , amenable curative surgery radiotherapy At least one prior chemotherapy palliative therapy Response Evaluation Criteria In Solid Tumors ( RECIST ) criteria disease status assessment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Concurrent administration tumor therapy Pregnant breast feed Serious concomitant disorder Inability unwillingness take folic acid vitamin B12 supplementation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>